TransMedics Group, Inc. (TMDX)
| Market Cap | 645.61M |
| Revenue (ttm) | 24.07M |
| Net Income (ttm) | -31.61M |
| Shares Out | 27.16M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $23.77 |
| Previous Close | $24.00 |
| Change ($) | -0.23 |
| Change (%) | -0.96% |
| Day's Open | 23.89 |
| Day's Range | 23.28 - 24.50 |
| Day's Volume | 153,043 |
| 52-Week Range | 10.50 - 24.50 |
TransMedics saw steady growth in 2019 after the public offering. Its transformative approach to organ transplantation has real benefits and seems to have traction as well, with Covid-19 only s...
ANDOVER, Mass., Dec. 24, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients wi...
ANDOVER, Mass., Dec. 23, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients wi...
LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road...
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
TransMedics Group's (TMDX) CEO Waleed Hassanein on Q3 2020 Results - Earnings Call Transcript
TransMedics (TMDX) delivered earnings and revenue surprises of 42.42% and 19.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ANDOVER, Mass., Nov. 4, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients wit...
ANDOVER, Mass., Oct. 29, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients wi...
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANDOVER, Mass., Oct. 21, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients wi...
ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for pati...
ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for pati...
TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2020 Results - Earnings Call Transcript
ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patie...
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patie...
ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patie...
TransMedics: A Medical Device Company Creating A Healthy Ecosystem
Shares slumped after the company announced it's raising capital.
ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patien...
ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patien...
Primary Effectiveness and Safety Endpoints Were Met. The OCS Liver Achieved Statistical Superiority of The Primary Effectiveness Endpoint by Demonstrating Significant Reduction of Early Allogr...
TransMedics Group's (TMDX) CEO Waleed Hassanein on Q1 2020 Results - Earnings Call Transcript
ANDOVER, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for pati...
TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q4 2019 Results - Earnings Call Transcript
Disrupting Organ Transplants: TransMedics And In-Kind Competitors
TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.
The current transportation process is riddled with inefficiencies and waste. TransMedics is on a mission to fix the problem and deliver huge returns for investors.
ANDOVER, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patie...
The IPO market is on fire right now. But not all the new IPO stocks make for promising investing opportunities to say the least.
About TMDX
TransMedics Group, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion apparatus, optimization, and monitoring syste... [Read more...]
| Industry Medical Devices | IPO Date May 2, 2019 |
| CEO Dr. Waleed H. Hassanein | Employees 109 |
| Stock Exchange NASDAQ | Ticker Symbol TMDX |
Financial Performance
In 2019, TMDX's revenue was $23.60 million, an increase of 81.33% compared to the previous year's $13.02 million. Losses were -$33.55 million, 41.2% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is 19.20, which is a decrease of -19.23% from the latest price.